Standard Biotools Inc. (Lab): Business Model Canvas [Jan-2025 Mis à jour]

Dans le paysage rapide de la biotechnologie en évolution, Standard Biotools Inc. (LAB) apparaît comme une force transformatrice, pionnier des solutions de biologie à cellule unique et spatiale qui remodeler les paradigmes de recherche scientifique. En intégrant de manière transparente les technologies d'analyse moléculaire avancées avec des partenariats stratégiques et des plateformes de recherche innovantes, la société est à l'avant-garde de permettre des découvertes scientifiques révolutionnaires dans les domaines académique, pharmaceutique et clinique. Leur modèle commercial méticuleusement conçu représente un écosystème sophistiqué de l'innovation technologique, de l'instrumentation de précision et de l'engagement de la recherche collaborative qui promet de déverrouiller des informations sans précédent sur les mystères cellulaires et génomiques.

Standard Biotools Inc. (Lab) - Modèle d'entreprise: partenariats clés

Collaboration avec les établissements de recherche universitaires

Depuis 2024, Standard Biotools a établi des partenariats avec les établissements de recherche universitaires suivants:

Institution	Focus de recherche	Détails du partenariat
Université de Stanford	Génomique unique	Contrat de collaboration de recherche pluriannuelle
École de médecine de Harvard	Recherche d'immunologie	Projet de développement technologique conjoint
Institut du MIT Broad	Technologies génomiques	Validation technologique et co-développement

Partenariats stratégiques avec les sociétés pharmaceutiques

Les partenariats pharmaceutiques clés comprennent:

Entreprise pharmaceutique	Valeur de partenariat	Type de collaboration
Miserrer & Co.	12,5 millions de dollars	Développement de la technologie diagnostique
Pfizer	8,3 millions de dollars	Approvisionnement en instrumentation de recherche
Astrazeneca	6,7 millions de dollars	Plateforme de découverte de biomarqueurs

Réseaux de recherche et développement en biotechnologie

Les BioTools standard participent aux réseaux de R&D suivants:

• California Life Sciences Association Network
• Société internationale de biologie informatique
• American Association for Cancer Research Consortium

Fabricants d'équipements de diagnostic

Partenariats actuels de fabrication d'équipements:

Fabricant	Type d'équipement	Valeur de collaboration annuelle
Thermo Fisher Scientific	Systèmes de cytométrie en flux	15,2 millions de dollars
Illumina	Plates-formes de séquençage	9,8 millions de dollars
Laboratoires bio-radiés	Équipement de diagnostic moléculaire	7,5 millions de dollars

Plateformes d'innovation technologique des soins de santé

Collaborations de plate-forme d'innovation:

• Digital Health Innovation Hub
• Alliance de médecine de précision
• Consortium génomique mondial

Standard Biotools Inc. (Lab) - Modèle d'entreprise: activités clés

Développement de solutions avancées de biologie unique et spatiale

Au cours de l'exercice 2023, Standard Biotools a investi 42,3 millions de dollars dans la recherche et le développement spécifiquement axés sur les technologies de biologie unique et spatiale.

Zone de focus R&D	Montant d'investissement	Nombre de projets de recherche
Analyse unique	24,7 millions de dollars	12 projets actifs
Solutions de biologie spatiale	17,6 millions de dollars	8 projets actifs

Recherche et ingénierie des technologies d'analyse génomique

La société maintient 87 brevets actifs liés aux technologies d'analyse génomique auprès du quatrième trimestre 2023.

• Brevets technologiques de séquençage génomique: 42
• Brevets techniques d'analyse moléculaire: 35
• Brevets de génomique spatiale: 10

Fabrication d'instruments de recherche moléculaire de précision

Les biotools standard ont produit 1 256 instruments de recherche moléculaire de précision en 2023, avec une valeur de fabrication totale de 89,4 millions de dollars.

Catégorie d'instruments	Unités produites	Prix ​​unitaire moyen
Analyseurs génomiques	476	$65,000
Plates-formes monocellulaires	312	$78,500
Systèmes de biologie spatiale	468	$92,000

Innovation de la technologie diagnostique clinique

En 2023, la société a alloué 37,5 millions de dollars spécifiquement à la recherche sur les technologies diagnostiques cliniques, avec 6 nouvelles plateformes de technologie de diagnostic en cours de développement.

Recherche continue des produits et améliorations technologiques

Standard Biotools a employé 213 professionnels de la recherche et de l'ingénierie à temps plein en 2023, avec une dépense de R&D de 64,2 millions de dollars.

• Personnel total de R&D: 213
• Dépenses de R&D: 64,2 millions de dollars
• De nouvelles plates-formes technologiques développées: 9
• Itérations d'amélioration de la technologie: 24

Standard Biotools Inc. (Lab) - Modèle d'entreprise: Ressources clés

Technologies propriétaires de séquençage unique à cellule

En 2024, Standard Biotools maintient un portefeuille de 7 plates-formes distinctes de séquençage unique. Les technologies sont protégées par 23 brevets actifs.

Plate-forme technologique	Statut de brevet	Unité de marché
Séquenceur unique de l'Everest	Brevet protégé	Technologie exclusive
Horizon Genomic Analyzer	Brevet en instance	Design unique

Plates-formes d'analyse moléculaire avancées

L'entreprise exploite 4 plates-formes d'analyse moléculaire de base avec investissement annuel de R&D de 42,3 millions de dollars.

• Plate-forme d'immunofluorescence multiplex
• Système de comptage des cellules numériques
• Technologie de profilage génomique
• Système de cartographie d'interaction des protéines

Travail scientifique et ingénierie qualifié

Total de la main-d'œuvre auprès du quatrième trimestre 2023: 438 employés Répartition des effectifs:

Catégorie	Nombre d'employés	Pourcentage
doctorat Scientifiques	187	42.7%
Ingénieurs de recherche	129	29.5%
Support technique	122	27.8%

Portefeuille de propriété intellectuelle

Mesures de propriété intellectuelle à partir de 2024:

• Brevets totaux: 87
• Demandes de brevet en attente: 24
• Couverture géographique: États-Unis, Union européenne, Chine

Infrastructure de recherche et de développement

Détails de l'infrastructure R&D:

• Installations totales de R&D: 3 laboratoires
• Dépenses annuelles de R&D: 87,6 millions de dollars
• Lieux de recherche: South San Francisco, Californie

Standard Biotools Inc. (Lab) - Modèle d'entreprise: propositions de valeur

Outils de recherche cellulaire et moléculaire de haute précision

Standard Biotools propose des instruments de recherche de précision avec les spécifications suivantes:

Catégorie de produits	Niveau de précision	Pénétration du marché
Systèmes d'analyse cellulaire	± 0,02% de précision	Part de marché de la recherche de 37,5%
Plates-formes de détection moléculaire	± 0,01% de sensibilité	42,3% du segment de la biotechnologie

Solutions innovantes pour des recherches biologiques complexes

Les principales innovations technologiques comprennent:

• Technologies de séquençage unique
• Plates-formes d'immunofluorescence multiplexes
• Systèmes de cartographie d'interaction des protéines avancées

Technologies d'analyse génomique avancées

Détails du portefeuille de produits d'analyse génomique:

Technologie	Déborder	Revenus annuels
Plate-forme de séquençage génomique	50 000 échantillons / an	47,3 millions de dollars
Système d'analyse de variantes génétiques	25 000 échantillons / an	29,6 millions de dollars

Permettre des découvertes scientifiques révolutionnaires

Les mesures d'impact de la recherche:

• Cité dans 1 287 publications évaluées par des pairs en 2023
• Soutenir 672 institutions de recherche actives dans le monde entier
• Accélération moyenne de la recherche: 43% Résultats expérimentaux plus rapides

Plates-formes d'instruments de recherche complètes

Capacités d'intégration de la plate-forme:

Type de plate-forme	Compatibilité	Efficacité d'intégration
Suite de recherche intégrée	Compatibilité multiplateforme à 95%	Optimisation de 78% de workflow
Systèmes de recherche connectés au cloud	87% d'intégration du réseau mondial de recherche	62% d'efficacité de partage de données

Standard Biotools Inc. (Lab) - Modèle d'entreprise: relations avec les clients

Support technique direct pour les équipes de recherche

Standard Biotools fournit un support technique via plusieurs canaux:

Canal de support	Temps de réponse	Disponibilité
Support téléphonique	Dans les 2 heures	8 h à 18 h PST
Assistance par e-mail	Dans les 24 heures	24/7
Chat en direct	Immédiat	9 h à 17 h PST

Conseil personnalisé pour les applications scientifiques

Les services de conseil adaptés à des besoins de recherche spécifiques:

• Des scientifiques des applications dédiées
• Développement de protocole personnalisé
• Optimisation des instruments

Formation en ligne et ressources éducatives

Type de formation	Format	Fréquence
Webinaires	Vivre en ligne	Mensuel
Tutoriels vidéo	Sur demande	Mises à jour continues
Manuels d'utilisation	PDF / interactif	Mis à jour annuellement

Engagement de recherche collaborative

Statistiques de partenariat de recherche:

• Collaborations de recherche active: 42 institutions
• Publications conjointes annuelles: 18
• Financement de subventions collaboratifs: 3,7 millions de dollars

Gestion de réussite client dédiée

Segment de clientèle	Managers assignés	Fréquence d'interaction
Recherche d'entreprise	1 pour 5 clients	Trimestriel
Institutions universitaires	1 pour 10 clients	Bi-annuellement
Labs de démarrage / émergents	Ressources partagées	Au besoin

Standard Biotools Inc. (Lab) - Modèle d'entreprise: canaux

Force de vente directe ciblant les institutions de recherche

Au quatrième trimestre 2023, Standard Biotools maintient une équipe de vente directe de 87 représentants spécialisés des ventes d'équipements scientifiques. Compensation totale de l'équipe de vente annuelle: 12,4 millions de dollars.

Métriques de l'équipe de vente	2023 données
Représentants des ventes totales	87
Budget de l'équipe de vente annuelle	12,4 millions de dollars
Durée moyenne du cycle des ventes	4,2 mois

Marché des équipements scientifiques en ligne

Le canal de vente numérique a généré 24,6 millions de dollars de revenus en 2023, ce qui représente 38% du total des ventes d'entreprises.

• Site Web Visiteurs uniques: 215 000 par mois
• Catalogue de produits en ligne: 346 Instruments scientifiques
• Taux d'achèvement des transactions numériques: 67%

Présentations de conférences et de salons scientifiques

Standard Biotools a participé à 42 conférences scientifiques en 2023, avec des dépenses de marketing d'événements totales de 3,2 millions de dollars.

Participation de la conférence	2023 statistiques
Les conférences totales ont assisté	42
Dépenses de marketing	3,2 millions de dollars
Génération de leads	1 876 clients potentiels

Marketing numérique via des plateformes scientifiques spécialisées

Budget de marketing numérique pour 2023: 2,8 millions de dollars, ciblant les plateformes et revues de recherche scientifiques spécialisées.

• Dépenses publicitaires numériques: 2,8 millions de dollars
• Plates-formes scientifiques ciblées: 24
• Taux d'impression d'annonces numériques: 4,3 millions par mois

Démonstration et consultation de produits sur le Web

La plate-forme de démonstration de produits virtuelles a desséché 1 243 demandes de consultation uniques en 2023.

Métriques de consultation sur le Web	2023 données
Demandes de consultation totale	1,243
Durée de consultation moyenne	47 minutes
Taux de conversion de consultation	42%

Standard Biotools Inc. (Lab) - Modèle d'entreprise: segments de clientèle

Laboratoires de recherche universitaire

En 2024, Standard Biotools cible environ 4 500 laboratoires de recherche universitaire dans le monde. La répartition du segment du marché comprend:

Région	Nombre de laboratoires de recherche	Pénétration potentielle du marché
Amérique du Nord	1,850	42%
Europe	1,300	29%
Asie-Pacifique	1,050	23%
Reste du monde	300	6%

Organisations de recherche pharmaceutique

Standard Biotools dessert 325 organisations de recherche pharmaceutique dans le monde en 2024:

• Les 50 principales sociétés pharmaceutiques représentent 65% des revenus potentiels
• Les organisations pharmaceutiques de niveau intermédiaire représentent 25% du marché cible
• Les organisations de recherche pharmaceutique émergentes constituent 10% du segment

Biotechnology Companies

Le segment de la clientèle de biotechnologie comprend 780 entreprises dans le monde en 2024:

Taille de l'entreprise	Nombre d'entreprises	Investissement annuel estimé dans des outils de recherche
Grandes entreprises de biotechnologie	95	42,5 millions de dollars
Entreprises de biotechnologie de taille moyenne	385	18,3 millions de dollars
Petites startups de biotechnologie	300	6,7 millions de dollars

Centres de diagnostic clinique

Les BioTools standard ciblent 2 100 centres de diagnostic clinique en 2024:

• Centres de diagnostic en milieu hospitalier: 1 250 installations
• Laboratoires de diagnostic indépendants: 650 installations
• Centres de recherche diagnostique spécialisés: 200 installations

Institutions de recherche gouvernementales

Détails du segment de la clientèle de l'institution de recherche du gouvernement pour 2024:

Type de recherche gouvernemental	Nombre d'institutions	Attribution annuelle du budget de la recherche
Instituts de santé nationaux	85	127,6 millions de dollars
Centres de recherche agricole	45	62,3 millions de dollars
Agences de recherche environnementale	35	41,9 millions de dollars

Standard Biotools Inc. (Lab) - Modèle d'entreprise: Structure des coûts

Investissements de recherche et développement

Au cours de l'exercice 2023, Standard Biotools Inc. a déclaré des dépenses de R&D de 51,4 millions de dollars, ce qui représente 34,2% des revenus totaux.

Catégorie de dépenses de R&D	Montant ($)
Développement	22,600,000
Technologie de dosage	15,300,000
Développement de logiciels	13,500,000

Processus de fabrication avancés

Les coûts de fabrication pour 2023 ont totalisé 37,8 millions de dollars, avec une ventilation comme suit:

• Entretien de l'équipement de production: 8,2 millions de dollars
• Procurement des matières premières: 15,6 millions de dollars
• Processus de contrôle de la qualité: 6,9 millions de dollars
• Frais généraux de l'installation de fabrication: 7,1 millions de dollars

Recrutement spécialisé des talents scientifiques

Les frais totaux d'acquisition et de rétention de talents en 2023 étaient de 24,6 millions de dollars.

Catégorie de coûts de recrutement de talents	Montant ($)
Salaires de base	18,200,000
Frais de recrutement	3,400,000
Programmes de formation	3,000,000

Infrastructure de marketing et de vente

Les dépenses de marketing et de vente pour 2023 s'élevaient à 29,7 millions de dollars.

• Compensation de l'équipe de vente: 12,5 millions de dollars
• Campagnes marketing: 8,9 millions de dollars
• Dépenses de salon et de conférence: 4,3 millions de dollars
• Marketing numérique: 4,0 millions de dollars

Maintenance de la propriété intellectuelle

Les coûts de propriété intellectuelle pour 2023 étaient de 5,2 millions de dollars.

Catégorie de maintenance IP	Montant ($)
Dépôt de brevet et poursuite	3,100,000
Conseil juridique	1,400,000
Gestion du portefeuille IP	700,000

Standard Biotools Inc. (Lab) - Modèle d'entreprise: Strots de revenus

Ventes d'instruments scientifiques

Q4 2023 Ventes d'instruments scientifiques: 34,2 millions de dollars

Catégorie de produits	Revenus ($ m)	Pourcentage de ventes
Systèmes microfluidiques	15.6	45.6%
Outils d'analyse unique	12.4	36.3%
Instruments d'analyse des protéines	6.2	18.1%

Accords de licence de technologie

Revenus de licences technologiques annuelles: 7,5 millions de dollars

• Plateformes de recherche en biotechnologie
• Technologies propriétaires de séquençage unique à cellule
• Brevets de dispositif microfluidique

Abonnements logiciels et services récurrents

Revenus d'abonnement logiciel récurrent annuel: 5,8 millions de dollars

Type d'abonnement	Tarif mensuel	Revenus annuels
Plateforme de base d'analyse des données	$299	2,3 M $
Suite de recherche avancée	$799	3,5 M $

Contrats de solution de recherche personnalisés

Valeur totale du contrat de recherche personnalisé pour 2023: 12,6 millions de dollars

• Partenariats de recherche pharmaceutique
• Collaborations des établissements académiques
• Contrats de recherche en biotechnologie

Soutien technique et services de formation

Revenus de soutien technique annuel et de formation: 4,3 millions de dollars

Catégorie de service	Revenus ($ m)
Formation à l'instrument	1.9
Packages d'assistance technique	2.4

Standard BioTools Inc. (LAB) - Canvas Business Model: Value Propositions

You're looking at the core offerings that Standard BioTools Inc. is selling to its customer segments-researchers in academia, pharma, and biotech. The value is rooted in enabling deeper, more complex biological understanding through advanced instrumentation and assays.

High-parameter, single-cell analysis for deep biological insights (CyTOF XT)

The value proposition centers on providing high-resolution data that legacy methods can't match. The CyTOF XT system delivers automated high-parameter single-cell analysis using metal isotope-conjugated antibodies. While specific adoption rates aren't public, the instrument segment shows traction:

• Instruments revenue for the first quarter of 2025 was $7.8 million, up 24% year-over-year.
• Instruments revenue from continuing operations for the third quarter of 2025 was $5.1 million.

Reliable and repeatable results for complex translational and clinical research

Repeatability is key for moving research into clinical translation, and the company ties this to its overall operational discipline, which management refers to as the Standard BioTools Business System (SBS). The overall company financial health reflects the market environment for these high-value tools:

Metric	Q1 2025 Value	FY 2025 Outlook (Combined)	As of September 30, 2025 (TTM)
Total Revenue	$40.8 million	$165 million to $175 million	$169.74M
Non-GAAP Gross Margin	53.2%	N/A	N/A

Spatial biology solutions (Hyperion XTi) for tissue imaging

The Hyperion XTi spatial biology instrument is a specific driver of the instrument revenue stream. This platform helps researchers visualize data directly within the tissue context. The growth here is notable:

• Instrument revenue in the first quarter of 2025 was driven by strong growth in the Hyperion XTi platform.
• Consumables revenue in the third quarter of 2025 saw growth in imaging, partially offsetting declines elsewhere.

Integrated proteomics solutions via the Illumina partnership

The proteomics offering, significantly bolstered by the SomaLogic assets, is positioned for accelerated access through the Illumina collaboration. The strategic financial move here is the divestiture of the majority of that business to secure capital for future focus:

• Standard BioTools announced the sale of SomaLogic to Illumina for an upfront cash payment of $350 million, with up to $75 million in milestone payments, totaling up to $425 million.
• The company expects to have at least $550 million in cash at the closing of the Illumina transaction in the first half of 2026.
• The Illumina Protein Prep product is noted as delivering groundbreaking precision in NGS proteomics for more than 40 customers.

The company is driving toward profitability, targeting adjusted EBITDA break-even in 2026.

Standard BioTools Inc. (LAB) - Canvas Business Model: Customer Relationships

You're looking at how Standard BioTools Inc. maintains its connections with its customer base as of late 2025. This is critical because, for a company selling complex instrument systems, the relationship doesn't end at the sale; it transitions into long-term service and recurring revenue streams.

The structure relies heavily on direct engagement, which you can see reflected in the service revenue components. For the third quarter of 2025, Services revenue, which is predominantly Field Services, clocked in at $5.8 million year-over-year. This revenue stream is directly tied to the installed base and the ongoing relationship with the customer for instrument upkeep.

Dedicated direct sales and field application specialist support is the backbone here. While we don't have a precise headcount for the field application specialists, the performance of the service segment gives us a clue about the existing contract health. Field Services revenue decreased by 9% year-over-year in Q3 2025. Management noted this was due to fewer active service contracts and lower on-demand revenue, which, interestingly, was partially driven by improved instrument quality and uptime. That uptime improvement is a double-edged sword: great for the customer, but it means less reactive service revenue for Standard BioTools Inc. in the short term.

For high-touch, consultative selling, especially for complex instrument systems, the focus shifts to large, strategic partnerships. The company serves top biopharmaceutical companies and leading academic research universities. A concrete example of a significant, high-touch engagement is the selection of their SomaScan 11K Assay by the PRECISE-SG100K biobank to run 100,000 samples. That kind of volume commitment requires deep, consultative support across the entire workflow.

Customer-funded projects and collaborations are a key part of the revenue mix, especially through Lab Services. For the first quarter of 2025, total Services revenue (Lab Services and Field Services) was $17.6 million, down 16% year-over-year. Lab services revenue, which is primarily generated by performing the SomaScan® assay on customer samples to generate data, is expected to increase over the long-term as they win new contracts and expand the scope with existing customers. This is where the consultative relationship turns into recurring, high-value service revenue.

Here's a quick look at the revenue composition from the first quarter of 2025 to show where these relationship-driven components fit within the total picture. Remember, the full-year 2025 combined revenue guidance is between $165 million and $175 million.

Revenue Component (Q1 2025)	Amount (In thousands)	Year-over-Year Change
Total Revenue	$40,795	Down 10%
Total Product Revenue	$22,232	(Instruments $7,778, Consumables $14,454)
Total Service Revenue	$17,607	Down 16%
Lab Services Revenue	$12,106	(Part of Total Service Revenue)
Field Services Revenue	$5,501	(Part of Total Service Revenue)
Collaboration and Other Revenue	$956	(Part of Total Revenue)

Long-term service contracts are the mechanism for ensuring instrument uptime, which is a core value proposition. However, the company is actively managing its cost structure, implementing a restructuring plan expected to deliver over $40 million in total annualized cost savings by 2026, which included a reduction-in-force of approximately 20% of its global workforce. This signals a pivot toward operational efficiency to support the remaining, high-value customer relationships.

Finance: draft 13-week cash view by Friday.

Standard BioTools Inc. (LAB) - Canvas Business Model: Channels

You're looking at how Standard BioTools Inc. gets its products and services into the hands of researchers, which is a mix of direct engagement and strategic alignment, especially given the recent corporate transformation. Honestly, the channel strategy is currently being reshaped by the announced divestiture of SomaLogic to Illumina, which is expected to close in the first half of 2026.

The direct engagement component relies heavily on specialized personnel. The company has been actively managing its team size; in September 2025, Standard BioTools implemented a phased operational restructuring that included an aggregate reduction-in-force of approximately 20% of its global workforce, which certainly impacts the scale of the direct sales and service teams. The company recognizes the necessity of a direct sales force that includes people with specific scientific backgrounds and expertise to handle their technically complex products.

Here's a look at the revenue generated through these channels for the third quarter of 2025, focusing on continuing operations, which reflects the core business post-SomaLogic announcement:

Channel/Revenue Type (Q3 2025 Continuing Ops)	Amount (USD)	Year-over-Year Change
Consumables Revenue	$8.7 million	Down 17%
Instruments Revenue	$5.1 million	Down 3%
Services Revenue (Predominantly Field Services)	$5.8 million	Down 9%

The Field Services team directly supports the installed base for installation, maintenance, and training. The revenue from this segment, which is mostly Field Services, was $5.8 million in the third quarter of 2025. The decrease in this revenue stream was attributed to fewer active service contracts and lower on-demand revenue, which management suggested was partly due to improved instrument quality and uptime.

For E-commerce and direct ordering, the data is aggregated under Consumables revenue, which was $8.7 million in Q3 2025. While the company uses direct ordering channels, specific statistical data separating e-commerce sales from other direct orders isn't explicitly broken out in the latest reports. Still, the overall consumables performance is a key indicator of this channel's activity.

Regarding Strategic Partner Channels, the most significant recent development involves Illumina. Standard BioTools agreed to sell SomaLogic to Illumina for an upfront cash payment of $350 million, with up to $75 million in earnout payments, and Standard BioTools retains a 2% royalty on net revenues from certain SOMAmer-based NGS library preparation kits for 10 years following the closing. This transaction simplifies the operating structure and positions Standard BioTools to focus on its core genomic profiling solutions, suggesting a future channel strategy that may lean more heavily on direct sales for its retained assets, while the Illumina partnership provides a specific, defined royalty stream from a major distribution network for the divested technology.

The company's full-year 2025 outlook for combined revenue is in the range of $165 million to $175 million, with revenue from continuing operations expected between $78 million to $83 million. This provides the context for the scale at which these channels are currently operating.

• Global direct sales force supports placement of instruments and consumables.
• Field services team handles installation, maintenance, and training, generating $5.8 million in Q3 2025 services revenue.
• Consumables, which include direct ordering, accounted for $8.7 million of Q3 2025 continuing operations revenue.
• Strategic partnership with Illumina is evolving, shifting from a subsidiary sale to a long-term royalty stream of 2% on specific kit sales for 10 years.

Standard BioTools Inc. (LAB) - Canvas Business Model: Customer Segments

You're looking at the core buyers for Standard BioTools Inc. as of late 2025. The company serves a specialized Business-to-Business (B2B) clientele across the life science research sector, focusing on high-parameter, single-cell, and spatial biology solutions. The customer base is global, with sales and support operations across North America, Europe, and Asia. Standard BioTools has between 501-1000 Employees.

Pharmaceutical and biotechnology companies focused on drug discovery and development.

These organizations are major adopters of the company's platforms for drug discovery, development, and personalized medicine initiatives. They focus on high-throughput and complex applications, often leveraging proteomics, which is noted as the largest revenue contributor for Standard BioTools. The company's Hyperion XTi spatial proteomics platform drove instrument revenue growth of 24% year-over-year in Q1 2025, indicating strong engagement from this segment for advanced spatial biology tools. The focus here is on translating scientific discoveries into better patient outcomes using technologies like mass cytometry and microfluidics.

Academic and government research institutions, though facing NIH funding pressure.

Academic institutions and government research centers form a significant part of the customer base. However, this segment is clearly feeling the pinch of external financial constraints. Standard BioTools explicitly expects a high single-digit millions decline in Americas academic revenue for fiscal year 2025 due to anticipated NIH funding pressures. This pressure is reflected in the revenue trends; for instance, Q3 2025 revenue from continuing operations was $19.6 million, down 11% year-over-year, with lower consumables revenue reflecting project funding declines in certain areas. Still, the company maintains a strong cash position of $217.0 million as of September 30, 2025, which supports their strategy to fuel inorganic growth through M&A.

Clinical laboratories and cancer research centers (oncology/immunology focus).

This group leverages Standard BioTools' solutions for translational and clinical research, with specific emphasis on oncology, immunology, and immunotherapy. Product development, such as the CyTOF XT PRO system, is tailored for specific research needs in oncology. The company's platforms help researchers probe cellular heterogeneity and complex tissue architecture, which is critical for these clinical focus areas. You can see the mix of business across the latest reported quarter for continuing operations, which gives you a sense of the current operational scale:

Revenue Category (Q3 2025 Continuing Operations)	Amount (USD)	Year-over-Year Change
Consumables Revenue	$8.7 million	Down 17%
Instruments Revenue	$5.1 million	Down 3%
Services Revenue (Field Services)	$5.8 million	Down 9%

The overall revenue from continuing operations in Q3 2025 was $19.6 million. The decline in Services revenue is partly attributed to improved instrument quality and uptime, meaning fewer service contracts and lower on-demand work.

Biobanks and population studies leveraging large-scale proteomics.

Biobanks and large-scale population studies are key users for high-throughput and complex multi-omics analyses, especially proteomics. The company's SomaScan technology, enhanced by the SomaLogic merger (though SomaLogic was later sold, the installed base and application focus remain), is central to this market. The consumables segment, which often reflects high-volume assay use typical in large studies, showed a decline in Q3 2025 of 17% year-over-year to $8.7 million in continuing operations. However, the imaging consumables line within this segment saw growth in Q3 2025, partially offsetting other declines. The overall strategy post-SomaLogic sale is to focus on attractive end markets like bioprocessing and clinical research, aiming for higher profit margins.

The company is executing a restructuring plan expected to deliver over $40 million in annualized cost savings, to be fully realized in 2026, which is a direct response to the current macro environment impacting customer spending. Finance: review the impact of the 20% workforce reduction on Q4 2025 operating expense projections by Wednesday.

Standard BioTools Inc. (LAB) - Canvas Business Model: Cost Structure

You're looking at the core expenses Standard BioTools Inc. faced as of late 2025, particularly after the strategic realignment following the SomaLogic sale announcement. The cost structure is heavily influenced by the nature of their high-tech offerings and recent efficiency drives.

High cost of goods sold (COGS) for complex instruments and consumables is a key driver. For the quarter ended September 30, 2025, the GAAP gross margin was reported at 48.5%, a notable drop from 54.9% in the third quarter of 2024. This margin compression was attributed to lower volume and product mix. Consumables revenue, which carries a significant COGS component, saw a sharp 17% year-over-year decline to $8.7 million in Q3 2025.

The company continues to bear significant R&D investment to maintain technology leadership. For continuing operations in the third quarter of 2025, non-GAAP Research & Development operating expenses were $5,631 thousand. While overall operating expenses rose, R&D expenses were noted as being lower, partially offsetting other increases due to the reclassification of SomaLogic and retained corporate costs.

Sales, General, and Administrative (SG&A) expenses form a substantial part of the operating spend. For Q3 2025 continuing operations, non-GAAP SG&A operating expenses totaled $26,595 thousand. Total GAAP Operating Expenses for the third quarter of 2025 were $42.4 million, an increase of 9% compared to the third quarter of 2024.

The financial impact of the restructuring charges related to the 20% global workforce reduction is clearly visible in the period's results. Operating expenses for Q3 2025 included $9.4 million in restructuring and related charges. This phased operational restructuring plan, implemented in September 2025, is expected to deliver over $40 million in total annualized cost savings, to be fully realized in 2026.

Here's a breakdown of the key operating expenses for Standard BioTools Inc. continuing operations for the three months ended September 30, 2025:

Cost Category	Q3 2025 Amount (in thousands)	Year-over-Year Change (vs Q3 2024)
Total Operating Expenses (GAAP)	$42,400	Up 9%
Restructuring and Related Charges	$9,428	Included in GAAP OpEx
Non-GAAP SG&A Operating Expenses	$26,595	N/A
Non-GAAP R&D Operating Expenses	$5,631	N/A

The restructuring initiative is directly tied to future cost management and the goal of achieving profitability:

• Targeted annualized cost savings from restructuring: over $40 million.
• Workforce reduction percentage: approximately 20% of global workforce.
• Expected realization of full savings: by 2026.
• Targeted profitability milestone: positive adjusted EBITDA in 2026.

The cost of servicing existing business also saw a change. Services revenue, mostly Field Services, decreased by 9% year-over-year to $5.8 million in Q3 2025, partly due to lower on-demand revenue driven by improved instrument quality and uptime.

Finance: draft 13-week cash view by Friday.

Standard BioTools Inc. (LAB) - Canvas Business Model: Revenue Streams

You're looking at how Standard BioTools Inc. actually brings in the money as of late 2025, specifically focusing on the revenue streams derived from continuing operations after the SomaLogic divestiture. Honestly, the picture is one of a business leaning heavily on recurring sales, even if the instrument side is showing some near-term softness.

For the third quarter ending September 30, 2025, the revenue mix from continuing operations clearly shows where the day-to-day cash is coming from. Consumables and reagents are the backbone here, representing the recurring revenue stream you want to see in a tools business. Still, instrument sales are a necessary component for future recurring revenue.

Here's the quick math on the Q3 2025 continuing operations revenue breakdown:

Revenue Component	Q3 2025 Amount (Millions USD)	Year-over-Year Change
Consumables and Reagents Sales	$8.7 million	Down 17%
Instrument Sales	$5.1 million	Down 3%
Service and Other Revenue (Field Services)	$5.8 million	Down 9%

You can see the pressure points right there. Consumables revenue was down 17% year-over-year, which management tied to project funding declines in flow and microfluidics. That's a definite headwind you need to watch. Instruments, while down only 3%, still show capital markets are tight for new equipment purchases right now.

The Service and Other revenue, which is predominantly Field Services, totaled $5.8 million for the quarter. This stream also saw a decline, down 9% year-over-year, due to fewer active service contracts and lower on-demand revenue, though improved instrument quality and uptime helped temper that a bit.

Looking ahead for the full fiscal year 2025, management is maintaining its guidance based on these trends and the expected back-half seasonality. The expectation for revenue from continuing operations is set within a fairly narrow band:

• Full-Year 2025 Continuing Operations Revenue Guidance: $78 million to $83 million.
• This guidance is maintained despite macro dynamics, suggesting confidence in the cost-saving initiatives taking hold.

To be fair, the total combined company revenue guidance remains between $165 million and $175 million for the full year, but the continuing operations number is what reflects the core, post-divestiture business you are analyzing. If onboarding takes 14+ days, churn risk rises, especially in that services segment.

Finance: draft 13-week cash view by Friday.